Loss of cellular inhibitor of apoptosis protein 2 reduces atherosclerosis in atherogenic apoe-/- C57BL/6 mice on high-fat diet

Journal of the American Heart Association

Volumn 2, Issue 5, 2013, Pages

  Sleiman, Lyne ^a,b   Beanlands, Rob ^a,b   Hasu, Mirela ^a,b   Thabet, Mohamed ^a,b   Norgaard, Alex ^b   Chen, Y X ^b   Holcik, Martin ^c   Whitman, Stewart ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

Apoptosis; Atherosclerosis; C57BL 6 mice; cIAP2

Indexed keywords

ALPHA ACTIN; APOLIPOPROTEIN E; CD68 ANTIGEN; DNA NUCLEOTIDYLEXOTRANSFERASE; INHIBITOR OF APOPTOSIS PROTEIN 2; SCARLET RED; INHIBITOR OF APOPTOSIS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AORTA ROOT; ARTERY LESION; ARTICLE; ATHEROGENESIS; C57BL 6 MOUSE; CONTROLLED STUDY; DISEASE COURSE; LIPID DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; PROTEIN CONTENT; PROTEIN DEPLETION; PROTEIN DETERMINATION; SMOOTH MUSCLE CELL; TUNEL ASSAY; ANIMAL; APOPTOSIS; ATHEROSCLEROSIS; C57BL MOUSE; C57BL/6 MICE; CIAP2; GENETICS; PHYSIOLOGY;

APOPTOSIS; ATHEROSCLEROSIS; C57BL/6 MICE; CIAP2;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DIET, HIGH-FAT; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MICE; MICE, INBRED C57BL;

EID: 84891693286     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.113.000259     Document Type: Article

References (48)

1. Glass CK, and Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104:503-516.
2. Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol. 2011;31:1506-1516.
3. Kockx MM. Apoptosis in the atherosclerotic plaque: quantitative and qualitative aspects. Arterioscler Thromb Vasc Biol. 1998;18:1519-1522.
4. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol. 2005;25:2255-2264.
5. Kutuk O, Basaga H. Bcl-2 protein family: implications in vascular apoptosis and atherosclerosis. Apoptosis. 2006;11:1661-1675.
6. Meilhac O, Escargueil-Bland I, Thiers J-C, Salvayre R, Negre-Salvayre A. Bcl-2 alters the balance between apoptosis and necrosis, but does not prevent cell death induced by oxidized low density lipoproteins. FASEB J. 1999;13:485-494.
7. Arai S, Shelton JM, Chen M, Bradley MN, Castrillo A, Bookout AL, Mak PA, Edwards PA, Mangelsdorf DJ, Tontonoz P, Miyazaki T. A role for the apoptosis inhibitory factor AIM/Spa/Api6 in atherosclerosis development. Cell Metab. 2005;1:201-213.
8. Liu J, Thewke DP, Su YR, Linton MF, Fazio S, Sinensky MS. Reduced macrophage apoptosis is associated with accelerated atherosclerosis in low-density lipoprotein receptor-null mice. Arterioscler Thromb Vasc Biol. 2005;25:174-179.
9. Gonza'lez-Navarro H, Abu Nabah YN, Vinue A, Andres-Manzano MJ, Collado M, Serrano M, Andres V. p19ARF deficiency reduces macrophage vascular smooth muscle cell apoptosis and aggravates atherosclerosis. J Am Coll Cardiol. 2010;55:2258-2268.
10. Boestena LSM, Zadelaarb ASM, van Nieuwkoopa A, Hua L, Teunissec AFAS, Jochemsenc AG, Eversf B, van de Waterg B, Gijbels MJJ, Van Vlijmend BJM, Havekes LM, De Wintherh MPJ. Macrophage p53 controls macrophage death in atherosclerotic lesions of apolipoprotein E in deficient mice. Atherosclerosis. 2009;207:399-404.
11. Liston P, Roy N, Tamai K, Lefebvre C, Baird S, Cherton-Horvat G, Farahani R, McLean M, Ikeda JE, MacKenzie A, Korneluk RG. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature. 1996;379:349-353.
12. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol. 2002;3:401-410.
13. Duckett CS, Nava VE, Gedrich RW, Clem RJ, Van Dongen JL, Gilfillan MC, Shiels H, Hardwick JM, Thompson CB. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. EMBO J. 1996;15:2685-2694.
14. Deveraux QL, Reed JC. IAP family proteins-suppressors of apoptosis. Genes Dev. 1999;13:239-252.
15. Conte D, Holcik M, Lefebvre CA, Lacasse E, Picketts DJ, Wright KE, Korneluk RG. Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival. Mol Cell Biol. 2006;26:699-708.
16. Labbe K, McIntire CR, Doiron K, Leblanc PM, Saleh M. Cellular inhibitors of apoptosis proteins cIAP1 and cIAP2 are required for efficient caspase-1 activation by the inflammasome. Immunity. 2011;35:897-907.
17. Blanc-Brude OP, Teissier E, Castier Y, Lesèche G, Bijnens AP, Daemen M, Staels B, Mallat Z, Tedgui A. IAP survivin regulates atherosclerotic macrophage survival. Arterioscler Thromb Vasc Biol. 2007;27:901-907.
18. Moran EP, Agrawal DK. Increased expression of inhibitor of apoptosis proteins in atherosclerotic plaques of symptomatic patients with carotid stenosis. Exp Mol Pathol. 2007;83:11-16.
19. Boisvert WA, Spangenberg J, Curtiss LK. Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation. J Clin Invest. 1995;96:1118-1124.
20. Riches DW, Underwood GA. Expression of interferon-beta during the triggering phase of macrophage cytocidal activation. Evidence for an autocrine/paracrine role in the regulation of this state. J Biol Chem. 1991;266:24785-24792.
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
22. Daugherty A, Whitman SC. Quantification of atherosclerosis in mice. Methods Mol Biol. 2003;209:293-309.
23. Horrevoets AJG, Fontijn RD, van Zonneveld AJ, de Vries CJM, ten Cate JW, Pannekoek H. Vascular endothelial genes that are responsive to tumor necrosis factor-alpha in vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin, and two novel genes. Blood. 1999;93:3418-3431.
24. Cui X, Imaizumi T, Yoshida H, Tanji K, Matsumiya T, Satoh K. Lipopolysaccharide induces the expression of cellular inhibitor of apoptosis protein-2 in human macrophages. Biochim Biophys Acta. 2000;1524:178-182.
25. Rakesh K, AgrawalDK. Cytokines and growth factors in apoptosis and proliferation of vascular smooth muscle cells. Int Immunopharmacol. 2005;10:1487-1506.
26. Jia G, Aggarwal A, Tyndall SH, Agrawal DK. Tumor necrosis factor-a regulates p27 kit expression and apoptosis in smooth muscle cells of human carotid plaques via forkhead transcription factor O1. Exp Mol Pathol. 2011;90:1-8.
27. Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E, Arora V, Mak TW, Lacasse EC, Waring J, Korneluk RG. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA. 2008;105:11778-11783.
28. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci USA. 1997;94:10057-10062.
29. Samuel T, Welsh K, Lober T, Togo SH, Zapata JM, Reed JC. Distinct BIR domains of cIAP1 mediate binding to and ubiquitination of tumor necrosis factor receptor-associated factor 2 and second mitochondrial activator of caspases. J Biol Chem. 2006;281:1080-1090.
30. Zheng C, Kabaleeswaran V, Wang Y, Cheng G, Wu H. Crystal structures of the TRAF2:cIAP2 and the TRAF1:TRAF2:cIAP2 complexes: affinity, specificity and regulation. Mol Cell. 2012;38:101-113.
31. McComb S, Cheung HH, Korneluk RG, Wang S, Krishnan L, Sad S. cIAP1 and cIAP2 limit macrophage necroptosis by inhibiting Rip1 and Rip3 activation. Cell Death Differ. 2012;19:1791-1801.
32. Van Vlijmen BJ, Gerritsen G, Franken AL, Boesten LS, Kockx MM, Gijbels MJ, Vierboom MP, van Eck M, van De Water B, van Berkel TJ, Havekes LM. Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. Circ Res. 2001;88:780-786.
33. Liu JJ, Huang RW, Lin DJ, Peng J, Wu XY, Lin Q, Pan XL, Song YQ, Zhang MH, Hou M, Chen F. Expression of survivin and bax/bcl-2 in peroxisome proliferator activated receptor-gamma ligands induces apoptosis on human myeloid leukemia cells in vitro. Ann Oncol. 2005;16:455-459.
34. Whitman SC. A practical approach to using mice in atherosclerotic research. Clin Biochem Rev. 2004;25:81-93.
35. Schrijvers DM, De Meyer GR, Kockx MM, Herman AG, Martinet W. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25:1256-1261.
36. Daniel JM, Sedding DG. Circulation smooth muscle progenitor cells in arterial remodeling. J Mol Cell Cardiol. 2011;50:273-279.
37. Clarke MC, Littlewood TD, Figg N, Maguire JJ, Davenport AP, Goddard M, Bennett MR. Chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis and promotes calcification and medial degeneration. Circ Res. 2008;12:1529-1538.
38. Zoll J, Fontaine V, Gourdy P, Barateau V, Vilar J, Leroyer A, Lopes-Kam I, Mallat Z, Arnal JF, Henry P, Tobelem G, Tedgui A. Role of human smooth muscle cell progenitors in atherosclerotic plaque development and composition. Cardiovasc Res. 2008;77:471-480.
39. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 2000;14:2123-2133.
40. Shai SY, Sukhanov S, Higashi Y, Vaughn C, Kelly J, Delafontaine P. Smooth muscle cell-specific insulin-like growth factor-1 overexpression in Apoe/ mice does not alter atherosclerotic plaque burden but increases features of plaque stability. Arterioscler Thromb Vasc Biol. 2012;30:1916-1924.
41. Vukovic I, Arsenijevic N, Lackovic V, Todorovic V. The origin and differentiation potential of smooth muscle cells in coronary atherosclerosis. Exp Clin Cardiol. 2006;2:123-128.
42. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102:33-42.
43. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ, VauxDL. Identification of DIABLO, amammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 2000;102:43-53.
44. Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X, Shi Y. Structural basis of IAP recognition by Smac/DIABLO. Nature. 2000;408:1008-1012.
45. Lu J, McEachern D, Sun H, Bai L, Peng Y, Qiu S, Miller R, Liao J, Yi H, Liu M, Bellail A, Hao C, Sun SY, Ting AT, Wang S. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Mol Cancer Ther. 2011;10:902-914.
46. Petersen SL, Peyton M, Minna JD, Wang X. Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP2 expression. Proc Natl Acad Sci USA. 2012;107:11936-11941.
47. Cossu F, Mastrangelo E, Milani M, Sorrentino G, Lecis D, Delia D, Manzoni L, Seneci P, Scolastico C, Bolognesi M. Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2. Biochem Biophys Res Commun. 2009;378:162-167.
48. Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, McEachern D, Liu L, Qiu S, Yang CY, Miller R, Yi H, Zhang T, Sun D, Kang S, Guo M, Leopold L, Yang D, Wang S. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitors of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem. 2011;19:2714-2726.